Hydroxychloroquine in Stage 1 Type 1 Diabetes.
Libman I, Bingley P, Becker D, Buckner J, DiMeglio L, Gitelman S, Greenbaum C, Haller M, Ismail H, Krischer J, Moore W, Moran A, Muir A, Raman V, Steck A, Toledo F, Wentworth J, Wherrett D, White P, You L, Herold K, Steck A, Greenbaum C, Lord S, Monzavi R, Katz L, Goland R, Muir A, Apperson E, DiMeglio L, Cummings E, Weinstock R, Gaglia J, Campbell F, Cabrera S, Nakhle S, English P, Huynh T, Liljenquist D, Moudiotis C, Duke S, Bosi E, Griffin K, Borg H, Lernmark A, Flynn D, Wilson D, Craig M, Moore W, Wherrett D, Tatovich D, Gitelman S, Philipson L, Haller M, Knip M, Tsalikian E, Baidal D, Thomas I, Moran A, Libman I, White P, Raman V, Raleigh Z, Solorzano C, Rodriguez H, Russell W, So M, Colman P, Couper J, Sherr J. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care 2023, 46: 2035-2043. PMID: 37708415, PMCID: PMC10620539, DOI: 10.2337/dc23-1096.Peer-Reviewed Original ResearchConceptsAnnual ophthalmologic examinationsMedian Follow-UpStage 1 diseaseHydroxychloroquine armPreplanned secondary analysisAutoantibodies to GADData Safety Monitoring BoardAnti-insulin autoantibodiesSafety monitoring boardType 1 diabetesInnate immune responseOphthalmologic examinationPositive autoantibodiesAnti-GADHydroxychloroquine treatmentMonth 6Oral glucoseFollow-upDrug treatmentImmune responseHydroxychloroquineAutoantibodiesTransient decreaseMonitoring boardReduced titers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply